> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves J&J’s Icotyde for Plaque Psoriasis
- URL: https://www.fdaweb.com/fda-approves-j-js-icotyde-for-plaque-psoriasis/
- Published: 2026-03-18T12:00:00.000Z
- Updated: 2026-09-14T13:35:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160840

FDA has approved Johnson & Johnson’s Icotyde (icotrokinra) to treat moderate-to-severe plaque psoriasis in adults and some pediatric patients aged 12 and older who are candidates for systemic therapy or phototherapy. A company [statement](https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide?ref=fdaweb.com) says Icotyde is the only targeted oral peptide that precisely blocks the IL-23 receptor.

J&J says Icotyde met all primary efficacy endpoints and demonstrated a favorable safety profile across four ICONIC Phase 3 studies, including 2,500 patients.

Icotyde is described as the first and only targeted oral peptide designed to precisely block the IL-23 receptor, which underpins the inflammatory response in moderate-to-severe plaque psoriasis. It binds to the IL-23 receptor with high affinity and demonstrates potent inhibition of IL-23 signaling in human T-cells, J&J says.

The company says it is also studying Icotyde in active psoriatic arthritis, moderately-to-severely active ulcerative colitis, and moderately-to-severely active Crohn’s disease.